Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Sino Biopharmaceutical ( (HK:1177) ) has shared an update.
Sino Biopharmaceutical Limited announced that its drug TQB2102, a HER2 bispecific antibody-drug conjugate, has been included in China’s Breakthrough Therapeutic Designation process. This inclusion is expected to expedite the drug’s approval, offering a promising treatment for HER2 IHC 3+ advanced colorectal cancer, a condition with limited effective treatment options. The drug has shown a 34.8% objective response rate in clinical trials, indicating significant potential to improve patient outcomes in a field where current therapies have limited efficacy.
The most recent analyst rating on (HK:1177) stock is a Hold with a HK$8.00 price target. To see the full list of analyst forecasts on Sino Biopharmaceutical stock, see the HK:1177 Stock Forecast page.
More about Sino Biopharmaceutical
Sino Biopharmaceutical Limited is a company incorporated in the Cayman Islands, focusing on the development and commercialization of pharmaceutical products. The company is involved in creating innovative drugs, particularly in the oncology sector, and operates with a market focus on China.
YTD Price Performance: 147.15%
Average Trading Volume: 160,441,487
Technical Sentiment Signal: Buy
Current Market Cap: HK$139.5B
See more insights into 1177 stock on TipRanks’ Stock Analysis page.